Want to see JP:2395 full AI Analyst Report?
2395 Stock Chart & Stats
¥1622.00
¥20.00(1.21%)
At close: 4:00 PM EST
¥1622.00
¥20.00(1.21%)
Day’s Range― - ―
52-Week Range¥1,067.00 - ¥2,005.00
Previous CloseN/A
Volume203.40K
Average Volume (3M)231.41K
Market Cap
¥53.16B
Enterprise Value¥82.09K
Total Cash (Recent Filing)¥18.54B
Total Debt (Recent Filing)¥41.26B
Price to Earnings (P/E)11.6
Beta0.91
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.92%
Share Statistics
EPS (TTM)109.70
Shares Outstanding41,632,400
10 Day Avg. Volume314,150
30 Day Avg. Volume231,410
Financial Highlights & Ratios
PEG Ratio-1.77
Price to Book (P/B)1.37
Price to Sales (P/S)1.81
P/FCF Ratio18.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,640.00Price Target Upside1.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)94.9
Revenue Forecast (FY)¥38.37B
Bulls Say, Bears Say
Bulls Say
High MarginsHigh gross (~49%) and net (~14%) margins provide structural profitability and pricing power in preclinical services. These margins create a durable buffer against project timing variability, support reinvestment in specialized facilities and staff, and help sustain returns even if revenue growth moderates.
Fee-for-service ModelA core fee-for-service preclinical model aligns with the secular trend of pharma outsourcing, producing repeatable project revenues and multi-month contracts. Specialized testing and regulatory compliance increase barriers to entry, supporting client stickiness and longer-term revenue durability.
Operational Scale & ExpertiseAn international footprint and a sizable scientific workforce (1,522 employees) provide capacity to run complex, multi-study programs for larger clients. Scale, local regulatory experience and staff expertise are durable competitive advantages in non-clinical testing where accreditation and skilled personnel matter.
Bears Say
Rising LeverageDebt roughly equal to equity (debt-to-equity ~1.0) increases balance-sheet risk and reduces financial flexibility. Higher leverage raises interest sensitivity, limits ability to fund capex or acquisitions internally, and makes the business more vulnerable if profitability or cash flow weakens.
Weak Cash ConversionOperating cash flow at only ~21% of reported net income and volatile free cash flow (negative across 2023–2025, positive in 2026) indicate uneven cash conversion. This undermines the company’s ability to reliably fund dividends, pay down debt, or finance growth without external capital.
Softening Revenue & MarginsA ~2.5% revenue decline in 2026 together with margin compression since 2022–2023 suggests demand or pricing pressure and weaker momentum. Sustained top-line softness plus margin erosion would strain profit sustainability and limit free-cash generation over the medium term.
Shin Nippon Biomedical Laboratories, Ltd. News
2395 FAQ
What was Shin Nippon Biomedical Laboratories, Ltd.’s price range in the past 12 months?
Shin Nippon Biomedical Laboratories, Ltd. lowest stock price was ¥1067.00 and its highest was ¥2005.00 in the past 12 months.
What is Shin Nippon Biomedical Laboratories, Ltd.’s market cap?
Shin Nippon Biomedical Laboratories, Ltd.’s market cap is ¥53.16B.
When is Shin Nippon Biomedical Laboratories, Ltd.’s upcoming earnings report date?
Shin Nippon Biomedical Laboratories, Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 91 days.
How were Shin Nippon Biomedical Laboratories, Ltd.’s earnings last quarter?
Shin Nippon Biomedical Laboratories, Ltd. released its earnings results on Aug 05, 2026. The company reported ¥25.55 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Shin Nippon Biomedical Laboratories, Ltd. overvalued?
According to Wall Street analysts Shin Nippon Biomedical Laboratories, Ltd.’s price is currently Undervalued.
Does Shin Nippon Biomedical Laboratories, Ltd. pay dividends?
Shin Nippon Biomedical Laboratories, Ltd. pays a Semiannually dividend of ¥20 which represents an annual dividend yield of 3.92%. See more information on Shin Nippon Biomedical Laboratories, Ltd. dividends here
What is Shin Nippon Biomedical Laboratories, Ltd.’s EPS estimate?
Shin Nippon Biomedical Laboratories, Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shin Nippon Biomedical Laboratories, Ltd. have?
Shin Nippon Biomedical Laboratories, Ltd. has 41,632,400 shares outstanding.
What happened to Shin Nippon Biomedical Laboratories, Ltd.’s price movement after its last earnings report?
Shin Nippon Biomedical Laboratories, Ltd. reported an EPS of ¥25.55 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.498%.
Which hedge fund is a major shareholder of Shin Nippon Biomedical Laboratories, Ltd.?
Currently, no hedge funds are holding shares in JP:2395
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. operates as a global contract research organization (CRO), delivering comprehensive drug discovery and development services both in Japan and internationally. Its preclinical offerings encompass a wide array of laboratory services, including regulatory-compliant good laboratory practice (GLP) inspections. These studies cover general and specialized toxicity assessments, detailed pathological examinations, pharmacokinetic (PK) and pharmacodynamic (PD) analysis for biopharmaceuticals, immunotoxicity testing, and antibody production. The company also conducts investigations into reproductive and developmental toxicity, pharmacological mechanisms, and efficacy, alongside providing various imaging services. Furthermore, the organization specializes in developing and validating analytical methodologies, analyzing biological specimens, and determining pharmacokinetic parameters. It also conducts studies on absorption, distribution, metabolism, and excretion (ADME), often utilizing radioisotope-labeled compounds. Beyond preclinical and analytical work, it extends its expertise to clinical trial support through site management organization (SMO) services and broader clinical contract research organization (CRO) support. Its translational research division focuses on advancing novel medical solutions, such as the development of nasal drug delivery systems, nucleic acid-based adjuvants, and regenerative medicine therapies. Established in 1957, Shin Nippon Biomedical Laboratories, Ltd. maintains its headquarters in Tokyo, Japan.
2395 Stock 12 Month Forecast
Average Price Target
¥1,640.00
▲(1.11% Upside)